- Apricus Biosciences (APRI) gets national phase approval (the company's fifth) in Germany for Vitaros.
- The company says the five remaining European phase approvals should be obtainable in Q4 and Q1 2014.
- Vitaros' application for marketing approval is approved under the Decentralized Procedure. The Netherlands is the RMS.
- APRI has multiple partners for the ED treatment including Takeda (TKPHF.PK), Sandoz, and Abbott (ABT). (PR)
- APRI +10% premarket.
Apricus Biosciences jumps on German phase approval for Vitaros
Oct 7 2013, 08:41 ET